289 related articles for article (PubMed ID: 29985776)
1. Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents.
Jiang X; Chen X; Carpenter TJ; Wang J; Zhou R; Davis HM; Heald DL; Wang W
MAbs; 2018; 10(6):876-889. PubMed ID: 29985776
[TBL] [Abstract][Full Text] [Related]
2. Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans.
Jiang X; Chen X; Jaiprasart P; Carpenter TJ; Zhou R; Wang W
Eur J Pharm Sci; 2020 Apr; 146():105260. PubMed ID: 32058058
[TBL] [Abstract][Full Text] [Related]
3. T Cell-Activating Bispecific Antibodies in Cancer Therapy.
Trabolsi A; Arumov A; Schatz JH
J Immunol; 2019 Aug; 203(3):585-592. PubMed ID: 31332079
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
Lindhofer H; Menzel H; Günther W; Hültner L; Thierfelder S
Blood; 1996 Dec; 88(12):4651-8. PubMed ID: 8977258
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
7. A Modeling Framework to Characterize Cytokine Release upon T-Cell-Engaging Bispecific Antibody Treatment: Methodology and Opportunities.
Chen X; Kamperschroer C; Wong G; Xuan D
Clin Transl Sci; 2019 Nov; 12(6):600-608. PubMed ID: 31268236
[TBL] [Abstract][Full Text] [Related]
8. A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART
Betts A; Haddish-Berhane N; Shah DK; van der Graaf PH; Barletta F; King L; Clark T; Kamperschroer C; Root A; Hooper A; Chen X
AAPS J; 2019 May; 21(4):66. PubMed ID: 31119428
[TBL] [Abstract][Full Text] [Related]
9. Influence of the bispecific antibody IgG subclass on T cell redirection.
Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
[TBL] [Abstract][Full Text] [Related]
10. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
[TBL] [Abstract][Full Text] [Related]
11. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
Cheng M; Ahmed M; Xu H; Cheung NK
Int J Cancer; 2015 Jan; 136(2):476-86. PubMed ID: 24895182
[TBL] [Abstract][Full Text] [Related]
12. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
[TBL] [Abstract][Full Text] [Related]
13. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation.
Demanet C; Brissinck J; De Jonge J; Thielemans K
Blood; 1996 May; 87(10):4390-8. PubMed ID: 8639800
[TBL] [Abstract][Full Text] [Related]
15. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
[TBL] [Abstract][Full Text] [Related]
16. One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics.
Chen W; Yang F; Wang C; Narula J; Pascua E; Ni I; Ding S; Deng X; Chu ML; Pham A; Jiang X; Lindquist KC; Doonan PJ; Van Blarcom T; Yeung YA; Chaparro-Riggers J
MAbs; 2021; 13(1):1871171. PubMed ID: 33557687
[TBL] [Abstract][Full Text] [Related]
17. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
[TBL] [Abstract][Full Text] [Related]
18. Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity.
Campagne O; Delmas A; Fouliard S; Chenel M; Chichili GR; Li H; Alderson R; Scherrmann JM; Mager DE
Clin Cancer Res; 2018 Jun; 24(11):2631-2641. PubMed ID: 29463552
[No Abstract] [Full Text] [Related]
19. Characterization of a Novel Bispecific Antibody That Activates T Cells
Chornoguz O; Leettola CN; Leander K; Brosnan K; Emmell E; Chiu ML; Santulli-Marotto S
Monoclon Antib Immunodiagn Immunother; 2019 Dec; 38(6):242-254. PubMed ID: 31825302
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method.
Song L; Xue J; Zhang J; Li S; Liu D; Zhou T
Eur J Pharm Sci; 2021 Mar; 158():105584. PubMed ID: 33039565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
